The FDA asked Novo Nordisk and Eli Lilly to remove warnings about suicidal ideation or behavior from the labels of their blockbuster GLP-1 weight loss drugs.
Novo's Saxenda and Wegovy, as well as Lilly's Zepbound ...
↧